Inotiv Inc. reported financial results for the first quarter (Q1) of fiscal 2026, with total revenue reaching USD 120.88 million, representing an increase of 0.8% for the period ended December 31, 2025. Service revenue for the quarter was USD 59.72 million, while product revenue amounted to USD 61.16 million. The company reported an operating loss of USD 16.3 million for Q1 fiscal 2026, reflecting an increase of 5.3%. Inotiv Inc. continues to focus on providing nonclinical and analytical drug discovery and development services, as well as research models and related products and services. Management emphasized their commitment to increasing efficiency, improving data, and reducing the cost of bringing new drugs and medical devices through the discovery and preclinical phases of development. The company also highlighted its ongoing engagement with analysts and investors, with a webcast and conference call scheduled to discuss the latest results and business updates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inotiv Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9650917) on February 09, 2026, and is solely responsible for the information contained therein.